NewsBenzingaJasper Therapeutics nomina Jeet Mahal come direttore finanziario principale ad interim con effetto dal 9 ottobre 2026; Herb Cross si dimette dall’incarico di CFO con effetto dal 9 ottobre 2026 Jasper Therapeutics nomina Jeet Mahal come direttore finanziario principale ad interim con effetto dal 9 ottobre 2026; Herb Cross si dimette dall’incarico di CFO con effetto dal 9 ottobre 2026 Benzinga 2026.09.28 20:48 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
